Aurinia Pharmaceuticals Inc (AUPH) — Capital Reinvestment Ratio
Latest as of March 2026:
0.00x
Aurinia Pharmaceuticals Inc (AUPH) has a Capital Reinvestment Ratio of 0.00x as of March 2026, meaning it reinvests 0% of its operating cash flow ($32.56 Million) in capital expenditures ($39.00K). See Aurinia Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$32.56 Million
USD
Capital Expenditures
$39.00K
USD
Data as of
Mar 2026
Most recent filing
Aurinia Pharmaceuticals Inc Capital Reinvestment Ratio (2024–2025)
This chart tracks Aurinia Pharmaceuticals Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Aurinia Pharmaceuticals Inc (2024–2025)
Year-by-year Capital Reinvestment Ratio for Aurinia Pharmaceuticals Inc from 2024 to 2025. For live market cap and broader valuation context, see Aurinia Pharmaceuticals Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.00x | $135.66 Million | $252.00K | ▼ -70.7% |
| 2024 | 0.01x | $44.39 Million | $281.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow